Taiho Expands Cancer Pipeline With ADCs In $400m Araris Buy
Add-On To Japanese Pharma’s Small Molecule Efforts
Taiho’s acquisition of Swiss next-generation antibody-drug conjugate developer Araris is one of about 10 ADC deals so far in 2025. The companies previously partnered in 2023.
